{"filing":{"accession_number":"0001104659-26-107184","cik":"0001768946","ticker":null,"company_name":"Biophytis SA","form":"6-K","filing_date":"2026-09-14","report_date":"2026-09-11","primary_document":"tm2625280d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1768946/000110465926107184/tm2625280d1_6k.htm"},"events":[{"id":33059,"run_id":30386,"accession_number":"0001104659-26-107184","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This press release announces the completion of a €5.3 million capital increase through issuance of 101,923,092 new shares and 127,403,865 warrants, representing a 29.1% dilution to existing shareholders before warrant exercise and 20.3% after full warrant exercise. The placement was made to institutional investors with removal of preferential subscription rights, a classic dilutive private placement structure. The disclosure explicitly addresses shareholder dilution impact, noting a 1% pre-offering shareholder would hold 0.71% post-issuance and 0.57% if all warrants are exercised.","company_name":"Biophytis SA","ticker":null,"filing_date":"2026-09-14","form":"6-K","submitted_at":null,"items":[{"id":36391,"accession_number":"0001104659-26-107184","item_number":"EX-99.1","item_title":"tm2625280d1_ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This press release announces the completion of a €5.3 million capital increase through issuance of 101,923,092 new shares and 127,403,865 warrants, representing a 29.1% dilution to existing shareholders before warrant exercise and 20.3% after full warrant exercise. The placement was made to institutional investors with removal of preferential subscription rights, a classic dilutive private placement structure. The disclosure explicitly addresses shareholder dilution impact, noting a 1% pre-offering shareholder would hold 0.71% post-issuance and 0.57% if all warrants are exercised.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T10:04:54.548758+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36391,"accession_number":"0001104659-26-107184","item_number":"EX-99.1","item_title":"tm2625280d1_ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This press release announces the completion of a €5.3 million capital increase through issuance of 101,923,092 new shares and 127,403,865 warrants, representing a 29.1% dilution to existing shareholders before warrant exercise and 20.3% after full warrant exercise. The placement was made to institutional investors with removal of preferential subscription rights, a classic dilutive private placement structure. The disclosure explicitly addresses shareholder dilution impact, noting a 1% pre-offering shareholder would hold 0.71% post-issuance and 0.57% if all warrants are exercised.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T10:04:54.548758+00:00","company_name":"Biophytis SA","ticker":null,"filing_date":"2026-09-14"}]}